{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:43:07Z","timestamp":1775184187566,"version":"3.50.1"},"reference-count":209,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Angiogenesis, the formation of new blood vessels, is required for many pathologic processes, including invasive tumor growth as well as physiologic organ\/tissue maintenance. Angiogenesis during development and adulthood is likely regulated by a balance between endogenous proangiogenic and antiangiogenic factors. It is speculated that tumor growth requires disruption of such balance; thus, the angiogenic switch must be turned \u201con\u201d for cancer progression. If the angiogenic switch needs to be turned on to facilitate the tumor growth, the question remains as to what the physiologic status of this switch is in the adult human body; is it \u201coff,\u201d with inhibitors outweighing the stimulators, or maintained at a fine \u201cbalance,\u201d keeping the proangiogenic properties of many factors at a delicate \u201cactivity\u201d balance with endogenous inhibitors of angiogenesis. The physiologic status of this balance is important to understand as it might determine an individual's predisposition to turn the switch on during pathologic events dependent on angiogenesis. Conceivably, if the physiologic angiogenesis balance in human population exists somewhere between off and even balance, an individual's capacity and rate to turn the switch on might reflect their normal physiologic angiogenic status. In this regard, although extensive knowledge has been gained in our understanding of endogenous growth factors that stimulate angiogenesis, the activities associated with endogenous inhibitors are poorly understood. In this review, we will present an overview of the knowledge gained in studies related to the identification and characterization of 27 different endogenous inhibitors of angiogenesis.<\/jats:p>","DOI":"10.1158\/0008-5472.can-04-2427","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T21:37:49Z","timestamp":1126820269000},"page":"3967-3979","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":418,"title":["Endogenous Inhibitors of Angiogenesis"],"prefix":"10.1158","volume":"65","author":[{"given":"Pia","family":"Nyberg","sequence":"first","affiliation":[{"name":"Center for Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}]},{"given":"Liang","family":"Xie","sequence":"additional","affiliation":[{"name":"Center for Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}]},{"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[{"name":"Center for Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}]}],"member":"1086","published-online":{"date-parts":[[2005,5,16]]},"reference":[{"key":"2023011120084436700_B1","doi-asserted-by":"crossref","unstructured":"Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med\u20081995; 1: 27\u201331.","DOI":"10.1038\/nm0195-27"},{"key":"2023011120084436700_B2","doi-asserted-by":"crossref","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med\u20081971; 285: 1182\u20136.","DOI":"10.1056\/NEJM197111182852108"},{"key":"2023011120084436700_B3","doi-asserted-by":"crossref","unstructured":"Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell\u20081996; 86: 353\u201364.","DOI":"10.1016\/S0092-8674(00)80108-7"},{"key":"2023011120084436700_B4","doi-asserted-by":"crossref","unstructured":"Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol\u20082003; 13: 159\u201367.","DOI":"10.1016\/S1044-579X(02)00133-5"},{"key":"2023011120084436700_B5","doi-asserted-by":"crossref","unstructured":"Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest\u20081999; 103: 157\u20138.","DOI":"10.1172\/JCI6127"},{"key":"2023011120084436700_B6","doi-asserted-by":"crossref","unstructured":"Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol\u20082001; 33: 357\u201369.","DOI":"10.1016\/S1357-2725(01)00023-1"},{"key":"2023011120084436700_B7","doi-asserted-by":"crossref","unstructured":"Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol\u20081996; 8: 618\u201324.","DOI":"10.1016\/S0955-0674(96)80102-5"},{"key":"2023011120084436700_B8","doi-asserted-by":"crossref","unstructured":"Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem\u20081995; 64: 403\u201334.","DOI":"10.1146\/annurev.bi.64.070195.002155"},{"key":"2023011120084436700_B9","doi-asserted-by":"crossref","unstructured":"Madri JA. Extracellular matrix modulation of vascular cell behaviour. Transpl Immunol\u20081997; 5: 179\u201383.","DOI":"10.1016\/S0966-3274(97)80035-4"},{"key":"2023011120084436700_B10","unstructured":"Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res\u20082000; 60: 2520\u20136."},{"key":"2023011120084436700_B11","doi-asserted-by":"crossref","unstructured":"Grant DS, Kibbey MC, Kinsella JL, Cid MC, Kleinman HK. The role of basement membrane in angiogenesis and tumor growth. Pathol Res Pract\u20081994; 190: 854\u201363.","DOI":"10.1016\/S0344-0338(11)80989-1"},{"key":"2023011120084436700_B12","doi-asserted-by":"crossref","unstructured":"Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through \u03b11\u03b21 and \u03b12\u03b21 integrins. Proc Natl Acad Sci U S A\u20081997; 94: 13612\u20137.","DOI":"10.1073\/pnas.94.25.13612"},{"key":"2023011120084436700_B13","doi-asserted-by":"crossref","unstructured":"Bloch W, Forsberg E, Lentini S, et al. \u03b21 Integrin is essential for teratoma growth and angiogenesis. J Cell Biol\u20081997; 139: 265\u201378.","DOI":"10.1083\/jcb.139.1.265"},{"key":"2023011120084436700_B14","doi-asserted-by":"crossref","unstructured":"Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin \u03b11 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A\u20082000; 97: 2202\u20137.","DOI":"10.1073\/pnas.040378497"},{"key":"2023011120084436700_B15","doi-asserted-by":"crossref","unstructured":"Pozzi A, Wary KK, Giancotti FG, Gardner HA. Integrin \u03b11\u03b21 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol\u20081998; 142: 587\u201394.","DOI":"10.1083\/jcb.142.2.587"},{"key":"2023011120084436700_B16","doi-asserted-by":"crossref","unstructured":"Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene\u20082002; 21: 272\u201381.","DOI":"10.1038\/sj.onc.1205045"},{"key":"2023011120084436700_B17","doi-asserted-by":"crossref","unstructured":"Keller KM, Keller JM, Kuhn K. The C-terminus of type I collagen is a major binding site for heparin. Biochim Biophys Acta\u20081986; 882: 1\u20135.","DOI":"10.1016\/0304-4165(86)90047-4"},{"key":"2023011120084436700_B18","doi-asserted-by":"crossref","unstructured":"Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem\u20082000; 275: 1209\u201315.","DOI":"10.1074\/jbc.275.2.1209"},{"key":"2023011120084436700_B19","doi-asserted-by":"crossref","unstructured":"Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem\u20082003; 278: 37632\u20136.","DOI":"10.1074\/jbc.M307339200"},{"key":"2023011120084436700_B20","doi-asserted-by":"crossref","unstructured":"Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem\u20082000; 275: 8051\u201361.","DOI":"10.1074\/jbc.275.11.8051"},{"key":"2023011120084436700_B21","doi-asserted-by":"crossref","unstructured":"Yurchenco PD, O'Rear JJ. Basal lamina assembly. Curr Opin Cell Biol\u20081994; 6: 674\u201381.","DOI":"10.1016\/0955-0674(94)90093-0"},{"key":"2023011120084436700_B22","doi-asserted-by":"crossref","unstructured":"Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem\u20082003; 278: 4238\u201349.","DOI":"10.1074\/jbc.M210445200"},{"key":"2023011120084436700_B23","doi-asserted-by":"crossref","unstructured":"Hayashi K, Madri JA, Yurchenco PD. Endothelial cells interact with the core protein of basement membrane perlecan through \u03b21 and \u03b23 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol\u20081992; 119: 945\u201359.","DOI":"10.1083\/jcb.119.4.945"},{"key":"2023011120084436700_B24","doi-asserted-by":"crossref","unstructured":"Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R. The C-terminal domain V of perlecan promotes \u03b21 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem\u20081997; 250: 39\u201346.","DOI":"10.1111\/j.1432-1033.1997.t01-1-00039.x"},{"key":"2023011120084436700_B25","doi-asserted-by":"crossref","unstructured":"Talts JF, Andac Z, Gohring W, Brancaccio A, Timpl R. Binding of the G domains of laminin \u03b11 and \u03b12 chains and perlecan to heparin, sulfatides, \u03b1-dystroglycan and several extracellular matrix proteins. EMBO J\u20081999; 18: 863\u201370.","DOI":"10.1093\/emboj\/18.4.863"},{"key":"2023011120084436700_B26","doi-asserted-by":"crossref","unstructured":"O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell\u20081997; 88: 277\u201385.","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"2023011120084436700_B27","doi-asserted-by":"crossref","unstructured":"Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT. Isolation and characterization of the circulating form of human endostatin. FEBS Lett\u20081997; 420: 129\u201333.","DOI":"10.1016\/S0014-5793(97)01503-2"},{"key":"2023011120084436700_B28","doi-asserted-by":"crossref","unstructured":"Rehn M, Hintikka E, Pihlajaniemi T. Primary structure of the \u03b11 chain of mouse type XVIII collagen, partial structure of the corresponding gene, and comparison of the \u03b11(XVIII) chain with its homologue, the \u03b11(XV) collagen chain. J Biol Chem\u20081994; 269: 13929\u201335.","DOI":"10.1016\/S0021-9258(17)36737-6"},{"key":"2023011120084436700_B29","doi-asserted-by":"crossref","unstructured":"Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci U S A\u20081994; 91: 4229\u201333.","DOI":"10.1073\/pnas.91.10.4229"},{"key":"2023011120084436700_B30","doi-asserted-by":"crossref","unstructured":"Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol\u20082001; 20: 337\u201345.","DOI":"10.1016\/S0945-053X(01)00151-2"},{"key":"2023011120084436700_B31","doi-asserted-by":"crossref","unstructured":"Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature\u20081997; 390: 404\u20137.","DOI":"10.1038\/37126"},{"key":"2023011120084436700_B32","unstructured":"Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res\u20082002; 62: 1944\u20137."},{"key":"2023011120084436700_B33","doi-asserted-by":"crossref","unstructured":"Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun\u20081999; 258: 345\u201352.","DOI":"10.1006\/bbrc.1999.0595"},{"key":"2023011120084436700_B34","doi-asserted-by":"crossref","unstructured":"Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem\u20082002; 277: 16464\u20139.","DOI":"10.1074\/jbc.M112274200"},{"key":"2023011120084436700_B35","doi-asserted-by":"crossref","unstructured":"Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR\/Flk-1. J Biol Chem\u20082002; 277: 27872\u20139.","DOI":"10.1074\/jbc.M202771200"},{"key":"2023011120084436700_B36","doi-asserted-by":"crossref","unstructured":"Yin G, Liu W, An P, et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther\u20082002; 5: 547\u201354.","DOI":"10.1006\/mthe.2002.0590"},{"key":"2023011120084436700_B37","doi-asserted-by":"crossref","unstructured":"Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J\u20082001; 15: 1044\u201353.","DOI":"10.1096\/fsb2fj991083com"},{"key":"2023011120084436700_B38","doi-asserted-by":"crossref","unstructured":"Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell\u20082004; 13: 649\u201363.","DOI":"10.1016\/S1097-2765(04)00102-9"},{"key":"2023011120084436700_B39","doi-asserted-by":"crossref","unstructured":"Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A\u20082001; 98: 1024\u20139.","DOI":"10.1073\/pnas.98.3.1024"},{"key":"2023011120084436700_B40","doi-asserted-by":"crossref","unstructured":"Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by \u03b1v\u03b23 and \u03b15\u03b21 integrins. Proc Natl Acad Sci U S A\u20082003; 100: 4766\u201371.","DOI":"10.1073\/pnas.0730882100"},{"key":"2023011120084436700_B41","doi-asserted-by":"crossref","unstructured":"Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell\u20081998; 94: 625\u201334.","DOI":"10.1016\/S0092-8674(00)81604-9"},{"key":"2023011120084436700_B42","unstructured":"Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin \u03b15\u03b21 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res\u20082002; 62: 5580\u20139."},{"key":"2023011120084436700_B43","doi-asserted-by":"crossref","unstructured":"Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett\u20082003; 536: 19\u201324.","DOI":"10.1016\/S0014-5793(03)00003-6"},{"key":"2023011120084436700_B44","doi-asserted-by":"crossref","unstructured":"Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci U S A\u20082004; 101: 8005\u201310.","DOI":"10.1073\/pnas.0402551101"},{"key":"2023011120084436700_B45","doi-asserted-by":"crossref","unstructured":"Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood\u20082000; 95: 3403\u201311.","DOI":"10.1182\/blood.V95.11.3403"},{"key":"2023011120084436700_B46","doi-asserted-by":"crossref","unstructured":"Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell\u20082001; 7: 811\u201322.","DOI":"10.1016\/S1097-2765(01)00225-8"},{"key":"2023011120084436700_B47","doi-asserted-by":"crossref","unstructured":"Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J\u20081998; 17: 1656\u201364.","DOI":"10.1093\/emboj\/17.6.1656"},{"key":"2023011120084436700_B48","doi-asserted-by":"crossref","unstructured":"Sasaki T, Larsson H, Kreuger J, et al. Structural basis and potential role of heparin\/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J\u20081999; 18: 6240\u20138.","DOI":"10.1093\/emboj\/18.22.6240"},{"key":"2023011120084436700_B49","doi-asserted-by":"crossref","unstructured":"Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J\u20082002; 21: 6303\u201311.","DOI":"10.1093\/emboj\/cdf638"},{"key":"2023011120084436700_B50","doi-asserted-by":"crossref","unstructured":"Wickstrom SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004.","DOI":"10.1074\/jbc.M312921200"},{"key":"2023011120084436700_B51","unstructured":"Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res\u20082000; 60: 5410\u20133."},{"key":"2023011120084436700_B52","doi-asserted-by":"crossref","unstructured":"Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett\u20082002; 519: 147\u201352.","DOI":"10.1016\/S0014-5793(02)02742-4"},{"key":"2023011120084436700_B53","doi-asserted-by":"crossref","unstructured":"Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, 9 and -13. J Biol Chem 2003.","DOI":"10.1074\/jbc.M210325200"},{"key":"2023011120084436700_B54","unstructured":"Wickstrom SA, Veikkola T, Rehn M, Pihlajaniemi T, Alitalo K, Keski-Oja J. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res\u20082001; 61: 6511\u20136."},{"key":"2023011120084436700_B55","doi-asserted-by":"crossref","unstructured":"Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett\u20082000; 486: 247\u201351.","DOI":"10.1016\/S0014-5793(00)02249-3"},{"key":"2023011120084436700_B56","doi-asserted-by":"crossref","unstructured":"Ackley BD, Crew JR, Elamaa H, Pihlajaniemi T, Kuo CJ, Kramer JM. The NC1\/endostatin domain of Caenorhabditis elegans type XVIII collagen affects cell migration and axon guidance. J Cell Biol\u20082001; 152: 1219\u201332.","DOI":"10.1083\/jcb.152.6.1219"},{"key":"2023011120084436700_B57","doi-asserted-by":"crossref","unstructured":"Kuo CJ, LaMontagne KR Jr, Garcia-Cardena G, et al. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1\/endostatin domain. J Cell Biol\u20082001; 152: 1233\u201346.","DOI":"10.1083\/jcb.152.6.1233"},{"key":"2023011120084436700_B58","doi-asserted-by":"crossref","unstructured":"Kranenburg O, Bouma B, Kroon-Batenburg LM, et al. Tissue-type plasminogen activator is a multiligand cross-\u03b2 structure receptor. Curr Biol\u20082002; 12: 1833\u20139.","DOI":"10.1016\/S0960-9822(02)01224-1"},{"key":"2023011120084436700_B59","doi-asserted-by":"crossref","unstructured":"Olsen BR. From the editor's desk. Matrix Biol\u20082002; 21: 309\u201310.","DOI":"10.1016\/S0945-053X(02)00051-3"},{"key":"2023011120084436700_B60","doi-asserted-by":"crossref","unstructured":"Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII\/endostatin results in eye abnormalities. EMBO J\u20082002; 21: 1535\u201344.","DOI":"10.1093\/emboj\/21.7.1535"},{"key":"2023011120084436700_B61","doi-asserted-by":"crossref","unstructured":"Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun\u20081999; 255: 735\u20139.","DOI":"10.1006\/bbrc.1999.0248"},{"key":"2023011120084436700_B62","doi-asserted-by":"crossref","unstructured":"Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol\u20082000; 301: 1179\u201390.","DOI":"10.1006\/jmbi.2000.3996"},{"key":"2023011120084436700_B63","doi-asserted-by":"crossref","unstructured":"Ylikarppa R, Eklund L, Sormunen R, et al. Double knockout mice reveal a lack of major functional compensation between collagens XV and XVIII. Matrix Biol\u20082003; 22: 443\u20138.","DOI":"10.1016\/S0945-053X(03)00074-X"},{"key":"2023011120084436700_B64","doi-asserted-by":"crossref","unstructured":"Pasqualini R, Bourdoulous S, Koivunen E, Woods VL Jr, Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med\u20081996; 2: 1197\u2013203.","DOI":"10.1038\/nm1196-1197"},{"key":"2023011120084436700_B65","doi-asserted-by":"crossref","unstructured":"Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A\u20082001; 98: 620\u20134.","DOI":"10.1073\/pnas.98.2.620"},{"key":"2023011120084436700_B66","doi-asserted-by":"crossref","unstructured":"Yi M, Sakai T, Fassler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci U S A\u20082003; 100: 11435\u20138.","DOI":"10.1073\/pnas.1635112100"},{"key":"2023011120084436700_B67","doi-asserted-by":"crossref","unstructured":"Kalluri R. Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Symp Quant Biol\u20082002; 67: 255\u201366.","DOI":"10.1101\/sqb.2002.67.255"},{"key":"2023011120084436700_B68","doi-asserted-by":"crossref","unstructured":"Albig AR, Schiemann WP. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol\u20082004; 23: 367\u201379.","DOI":"10.1089\/104454904323145254"},{"key":"2023011120084436700_B69","doi-asserted-by":"crossref","unstructured":"Nguyen AD, Itoh S, Jeney V, et al. Fibulin-5 is a novel binding protein for extracellular superoxide dismutase. Circ Res\u20082004; 95: 1067\u201374.","DOI":"10.1161\/01.RES.0000149568.85071.FB"},{"key":"2023011120084436700_B70","doi-asserted-by":"crossref","unstructured":"Lee MJ, Roy NK, Mogford JE, Schiemann WP, Mustoe TA. Fibulin-5 promotes wound healing in vivo. J Am Coll Surg\u20082004; 199: 403\u201310.","DOI":"10.1016\/j.jamcollsurg.2004.04.021"},{"key":"2023011120084436700_B71","doi-asserted-by":"crossref","unstructured":"Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A\u20081990; 87: 6624\u20138.","DOI":"10.1073\/pnas.87.17.6624"},{"key":"2023011120084436700_B72","doi-asserted-by":"crossref","unstructured":"Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol\u20082000; 19: 597\u2013614.","DOI":"10.1016\/S0945-053X(00)00107-4"},{"key":"2023011120084436700_B73","doi-asserted-by":"crossref","unstructured":"Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol\u20082004; 36: 1070\u20138.","DOI":"10.1016\/j.biocel.2004.01.025"},{"key":"2023011120084436700_B74","doi-asserted-by":"crossref","unstructured":"Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1\/TSP2-null mice. Am J Pathol\u20082002; 161: 831\u20139.","DOI":"10.1016\/S0002-9440(10)64243-5"},{"key":"2023011120084436700_B75","doi-asserted-by":"crossref","unstructured":"Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol\u20081999; 155: 441\u201352.","DOI":"10.1016\/S0002-9440(10)65140-1"},{"key":"2023011120084436700_B76","doi-asserted-by":"crossref","unstructured":"Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A\u20082001; 98: 12485\u201390.","DOI":"10.1073\/pnas.171460498"},{"key":"2023011120084436700_B77","doi-asserted-by":"crossref","unstructured":"Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer\u20081996; 32A: 2394\u2013400.","DOI":"10.1016\/S0959-8049(96)00385-1"},{"key":"2023011120084436700_B78","doi-asserted-by":"crossref","unstructured":"Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer\u20081994; 59: 191\u20135.","DOI":"10.1002\/ijc.2910590209"},{"key":"2023011120084436700_B79","doi-asserted-by":"crossref","unstructured":"Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol\u20082001; 159: 1949\u201356.","DOI":"10.1016\/S0002-9440(10)63042-8"},{"key":"2023011120084436700_B80","unstructured":"Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, Blake DA. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1 [in process citation]. Invest Ophthalmol Vis Sci\u20082000; 41: 2378\u201388."},{"key":"2023011120084436700_B81","doi-asserted-by":"crossref","unstructured":"Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation\u20081999; 100: 1423\u201331.","DOI":"10.1161\/01.CIR.100.13.1423"},{"key":"2023011120084436700_B82","doi-asserted-by":"crossref","unstructured":"Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med\u20082002; 8: 349\u201357.","DOI":"10.1038\/nm0402-349"},{"key":"2023011120084436700_B83","doi-asserted-by":"crossref","unstructured":"Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A\u20081999; 96: 14888\u201393.","DOI":"10.1073\/pnas.96.26.14888"},{"key":"2023011120084436700_B84","doi-asserted-by":"crossref","unstructured":"Hawighorst T, Velasco P, Streit M, et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J\u20082001; 20: 2631\u201340.","DOI":"10.1093\/emboj\/20.11.2631"},{"key":"2023011120084436700_B85","unstructured":"Streit M, Stephen AE, Hawighorst T, et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res\u20082002; 62: 2004\u201312."},{"key":"2023011120084436700_B86","doi-asserted-by":"crossref","unstructured":"Noh YH, Matsuda K, Hong YK, et al. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol\u20082003; 121: 1536\u201343.","DOI":"10.1046\/j.1523-1747.2003.12643.x"},{"key":"2023011120084436700_B87","doi-asserted-by":"crossref","unstructured":"Monboisse JC, Garnotel R, Bellon G, et al. The \u03b13 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J Biol Chem\u20081994; 269: 25475\u201382.","DOI":"10.1016\/S0021-9258(18)47275-4"},{"key":"2023011120084436700_B88","doi-asserted-by":"crossref","unstructured":"Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the \u03b13 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem\u20081997; 272: 20395\u2013401.","DOI":"10.1074\/jbc.272.33.20395"},{"key":"2023011120084436700_B89","unstructured":"Shahan TA, Ziaie Z, Pasco S, et al. Identification of CD47\/integrin-associated protein and \u03b1(v)\u03b23 as two receptors for the \u03b13(IV) chain of type IV collagen on tumor cells. Cancer Res\u20081999; 59: 4584\u201390."},{"key":"2023011120084436700_B90","doi-asserted-by":"crossref","unstructured":"Maeshima Y, Colorado PC, Torre A, et al. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem\u20082000; 275: 21340\u20138.","DOI":"10.1074\/jbc.M001956200"},{"key":"2023011120084436700_B91","doi-asserted-by":"crossref","unstructured":"Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent \u03b1v\u03b23 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem\u20082000; 275: 23745\u201350.","DOI":"10.1074\/jbc.C000186200"},{"key":"2023011120084436700_B92","doi-asserted-by":"crossref","unstructured":"Pasco S, Ramont L, Maquart FX, Monboisse JC. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol\u20082004; 49: 221\u201333.","DOI":"10.1016\/j.critrevonc.2003.09.006"},{"key":"2023011120084436700_B93","doi-asserted-by":"crossref","unstructured":"Floquet N, Pasco S, Ramont L, et al. The antitumor properties of the \u03b13(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. J Biol Chem\u20082004; 279: 2091\u2013100.","DOI":"10.1074\/jbc.M307736200"},{"key":"2023011120084436700_B94","doi-asserted-by":"crossref","unstructured":"Imagawa W, Pedchenko VK, Helber J, Zhang H. Hormone\/growth factor interactions mediating epithelial\/stromal communication in mammary gland development and carcinogenesis. J Steroid Biochem Mol Biol\u20082002; 80: 213\u201330.","DOI":"10.1016\/S0960-0760(01)00188-1"},{"key":"2023011120084436700_B95","doi-asserted-by":"crossref","unstructured":"Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane derived tumstatin. J Biol Chem\u20082001; 276: 15240\u20138.","DOI":"10.1074\/jbc.M007764200"},{"key":"2023011120084436700_B96","doi-asserted-by":"crossref","unstructured":"Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to \u03b1(v)\u03b2(3) integrin and inhibits angiogenesis. J Biol Chem\u20082001; 276: 31959\u201368.","DOI":"10.1074\/jbc.M103024200"},{"key":"2023011120084436700_B97","doi-asserted-by":"crossref","unstructured":"Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science\u20082002; 295: 140\u20133.","DOI":"10.1126\/science.1065298"},{"key":"2023011120084436700_B98","doi-asserted-by":"crossref","unstructured":"Hutchings H, Ortega N, Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J\u20082003; 17: 1520\u20132.","DOI":"10.1096\/fj.02-0691fje"},{"key":"2023011120084436700_B99","doi-asserted-by":"crossref","unstructured":"Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV \u03b13 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via \u03b1V\u03b23 integrin. Cancer Cell\u20082003; 3: 589\u2013601.","DOI":"10.1016\/S1535-6108(03)00133-8"},{"key":"2023011120084436700_B100","doi-asserted-by":"crossref","unstructured":"Caudroy S, Cucherousset J, Lorenzato M, et al. Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas. Hum Pathol\u20082004; 35: 1218\u201322.","DOI":"10.1016\/j.humpath.2004.06.008"},{"key":"2023011120084436700_B101","doi-asserted-by":"crossref","unstructured":"McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol\u20082001; 13: 534\u201340.","DOI":"10.1016\/S0955-0674(00)00248-9"},{"key":"2023011120084436700_B102","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes\u20082004; 53: 1831\u201340.","DOI":"10.2337\/diabetes.53.7.1831"},{"key":"2023011120084436700_B103","doi-asserted-by":"crossref","unstructured":"Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res\u20081998; 8: 171\u20137.","DOI":"10.1038\/cr.1998.17"},{"key":"2023011120084436700_B104","doi-asserted-by":"crossref","unstructured":"Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B\/type IV collagenase (MMP-9). J Biol Chem\u20081997; 272: 28823\u20135.","DOI":"10.1074\/jbc.272.46.28823"},{"key":"2023011120084436700_B105","doi-asserted-by":"crossref","unstructured":"Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol\u20081998; 161: 6845\u201352.","DOI":"10.4049\/jimmunol.161.12.6845"},{"key":"2023011120084436700_B106","doi-asserted-by":"crossref","unstructured":"Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia\u20082001; 44: 757\u201365.","DOI":"10.1007\/s001250051685"},{"key":"2023011120084436700_B107","doi-asserted-by":"crossref","unstructured":"O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell\u20081994; 79: 315\u201328.","DOI":"10.1016\/0092-8674(94)90200-3"},{"key":"2023011120084436700_B108","doi-asserted-by":"crossref","unstructured":"Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry\u20081998; 37: 4699\u2013702.","DOI":"10.1021\/bi9731798"},{"key":"2023011120084436700_B109","doi-asserted-by":"crossref","unstructured":"Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell\u20081997; 88: 801\u201310.","DOI":"10.1016\/S0092-8674(00)81926-1"},{"key":"2023011120084436700_B110","doi-asserted-by":"crossref","unstructured":"O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem\u20081999; 274: 29568\u201371.","DOI":"10.1074\/jbc.274.41.29568"},{"key":"2023011120084436700_B111","doi-asserted-by":"crossref","unstructured":"Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem\u20081997; 272: 20641\u20135.","DOI":"10.1074\/jbc.272.33.20641"},{"key":"2023011120084436700_B112","doi-asserted-by":"crossref","unstructured":"Ji WR, Castellino FJ, Chang Y, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J\u20081998; 12: 1731\u20138.","DOI":"10.1096\/fasebj.12.15.1731"},{"key":"2023011120084436700_B113","doi-asserted-by":"crossref","unstructured":"Geiger JH, Cnudde SE. What the structure of angiostatin may tell us about its mechanism of action. J Thromb Haemost\u20082004; 2: 23\u201334.","DOI":"10.1111\/j.1538-7836.2004.00544.x"},{"key":"2023011120084436700_B114","doi-asserted-by":"crossref","unstructured":"Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A\u20081999; 96: 2811\u20136.","DOI":"10.1073\/pnas.96.6.2811"},{"key":"2023011120084436700_B115","doi-asserted-by":"crossref","unstructured":"Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem\u20082002; 277: 33564\u201370.","DOI":"10.1074\/jbc.M205514200"},{"key":"2023011120084436700_B116","doi-asserted-by":"crossref","unstructured":"Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin \u03b1(v)\u03b2(3) in endothelial cells. J Biol Chem\u20082001; 276: 39562\u20138.","DOI":"10.1074\/jbc.M101815200"},{"key":"2023011120084436700_B117","doi-asserted-by":"crossref","unstructured":"Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol\u20082001; 152: 1247\u201354.","DOI":"10.1083\/jcb.152.6.1247"},{"key":"2023011120084436700_B118","doi-asserted-by":"crossref","unstructured":"Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A\u20081998; 95: 5579\u201383.","DOI":"10.1073\/pnas.95.10.5579"},{"key":"2023011120084436700_B119","doi-asserted-by":"crossref","unstructured":"O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science\u20081999; 285: 1926\u20138.","DOI":"10.1126\/science.285.5435.1926"},{"key":"2023011120084436700_B120","doi-asserted-by":"crossref","unstructured":"Lee TH, Rhim T, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem\u20081998; 273: 28805\u201312.","DOI":"10.1074\/jbc.273.44.28805"},{"key":"2023011120084436700_B121","doi-asserted-by":"crossref","unstructured":"Kusafuka K, Hiraki Y, Shukunami C, Kayano T, Takemura T. Cartilage-specific matrix protein, chondromodulin-I (ChM-I), is a strong angio-inhibitor in endochondral ossification of human neonatal vertebral tissues in vivo: relationship with angiogenic factors in the cartilage. Acta Histochem\u20082002; 104: 167\u201375.","DOI":"10.1078\/0065-1281-00642"},{"key":"2023011120084436700_B122","doi-asserted-by":"crossref","unstructured":"Shukunami C, Yamamoto S, Tanabe T, Hiraki Y. Generation of multiple transcripts from the chicken chondromodulin-I gene and their expression during embryonic development. FEBS Lett\u20081999; 456: 165\u201370.","DOI":"10.1016\/S0014-5793(99)00931-X"},{"key":"2023011120084436700_B123","doi-asserted-by":"crossref","unstructured":"Hayami T, Shukunami C, Mitsui K, et al. Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett\u20081999; 458: 436\u201340.","DOI":"10.1016\/S0014-5793(99)01201-6"},{"key":"2023011120084436700_B124","doi-asserted-by":"crossref","unstructured":"Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun\u20081996; 226: 324\u20138.","DOI":"10.1006\/bbrc.1996.1355"},{"key":"2023011120084436700_B125","doi-asserted-by":"crossref","unstructured":"Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A\u20081993; 90: 10705\u20139.","DOI":"10.1073\/pnas.90.22.10705"},{"key":"2023011120084436700_B126","doi-asserted-by":"crossref","unstructured":"Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene\u20081998; 208: 297\u2013305.","DOI":"10.1016\/S0378-1119(98)00006-7"},{"key":"2023011120084436700_B127","doi-asserted-by":"crossref","unstructured":"He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol\u20081999; 13: 537\u201345.","DOI":"10.1210\/mend.13.4.0265"},{"key":"2023011120084436700_B128","unstructured":"Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR\/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ\u20081996; 7: 213\u201321."},{"key":"2023011120084436700_B129","doi-asserted-by":"crossref","unstructured":"Barleon B, Totzke F, Herzog C, et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem\u20081997; 272: 10382\u20138.","DOI":"10.1074\/jbc.272.16.10382"},{"key":"2023011120084436700_B130","doi-asserted-by":"crossref","unstructured":"Belgore FM, Blann AD, Lip GY. sFlt-1, a potential antagonist for exogenous VEGF. Circulation\u20082000; 102: E108\u20139.","DOI":"10.1161\/01.CIR.102.15.e108"},{"key":"2023011120084436700_B131","doi-asserted-by":"crossref","unstructured":"Yoshimura I, Mizuguchi Y, Miyajima A, Asano T, Tadakuma T, Hayakawa M. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol\u20082004; 171: 2467\u201370.","DOI":"10.1097\/01.ju.0000117801.04926.a8"},{"key":"2023011120084436700_B132","doi-asserted-by":"crossref","unstructured":"Ohtani K, Egashira K, Hiasa K, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation\u20082004; 110: 2444\u201352.","DOI":"10.1161\/01.CIR.0000145123.85083.66"},{"key":"2023011120084436700_B133","doi-asserted-by":"crossref","unstructured":"Mitsuyasu RT. Interferon \u03b1 in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol\u20081991; 79: 69\u201373.","DOI":"10.1111\/j.1365-2141.1991.tb08124.x"},{"key":"2023011120084436700_B134","unstructured":"Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon \u03b1 act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res\u20081998; 58: 5551\u20138."},{"key":"2023011120084436700_B135","doi-asserted-by":"crossref","unstructured":"Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem\u20081994; 55: 419\u201334.","DOI":"10.1002\/jcb.240550403"},{"key":"2023011120084436700_B136","doi-asserted-by":"crossref","unstructured":"Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-\u03b3 and IFN-\u03b2: critical role of STAT-1\u03b1. J Immunol\u20082001; 167: 5150\u20139.","DOI":"10.4049\/jimmunol.167.9.5150"},{"key":"2023011120084436700_B137","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-\u03b1 administration. Cancer Res\u20081998; 58: 808\u201314."},{"key":"2023011120084436700_B138","unstructured":"Ribatti D, Crivellato E, Candussio L, et al. Angiogenic activity of rat mast cells in the chick embryo chorioallantoic membrane is down-regulated by treatment with recombinant human \u03b1-2a interferon and partly mediated by fibroblast growth factor-2. Haematologica\u20082002; 87: 465\u201371."},{"key":"2023011120084436700_B139","doi-asserted-by":"crossref","unstructured":"Lopez-Ocejo O, Perea SE, Bequet-Romero M, Arana MJ, Lopez Saura P. Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-\u03b1. Biochem Biophys Res Commun\u20082000; 277: 410\u20136.","DOI":"10.1006\/bbrc.2000.3690"},{"key":"2023011120084436700_B140","unstructured":"Nilsson A, Janson ET, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during \u03b1-interferon treatment. Anticancer Res\u20082001; 21: 4087\u201390."},{"key":"2023011120084436700_B141","doi-asserted-by":"crossref","unstructured":"Sasamura H, Takahashi A, Miyao N, et al. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer\u20082002; 86: 768\u201373.","DOI":"10.1038\/sj.bjc.6600152"},{"key":"2023011120084436700_B142","doi-asserted-by":"crossref","unstructured":"Wang L, Wu WZ, Sun HC, et al. Mechanism of interferon \u03b1 on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg\u20082003; 7: 587\u201394.","DOI":"10.1016\/S1091-255X(03)00072-6"},{"key":"2023011120084436700_B143","doi-asserted-by":"crossref","unstructured":"Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem\u20081995; 270: 27348\u201357.","DOI":"10.1074\/jbc.270.45.27348"},{"key":"2023011120084436700_B144","doi-asserted-by":"crossref","unstructured":"Cozzolino F, Torcia M, Aldinucci D, et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci U S A\u20081990; 87: 6487\u201391.","DOI":"10.1073\/pnas.87.17.6487"},{"key":"2023011120084436700_B145","doi-asserted-by":"crossref","unstructured":"Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J\u20082004; 18: 161\u20133.","DOI":"10.1096\/fj.03-0483fje"},{"key":"2023011120084436700_B146","doi-asserted-by":"crossref","unstructured":"Volpert OV, Fong T, Koch AE, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med\u20081998; 188: 1039\u201346.","DOI":"10.1084\/jem.188.6.1039"},{"key":"2023011120084436700_B147","doi-asserted-by":"crossref","unstructured":"Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst\u20081995; 87: 581\u20136.","DOI":"10.1093\/jnci\/87.8.581"},{"key":"2023011120084436700_B148","doi-asserted-by":"crossref","unstructured":"Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood\u20081996; 87: 3877\u201382.","DOI":"10.1182\/blood.V87.9.3877.bloodjournal8793877"},{"key":"2023011120084436700_B149","doi-asserted-by":"crossref","unstructured":"Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood\u20081999; 93: 1612\u201321.","DOI":"10.1182\/blood.V93.5.1612.405a13_1612_1621"},{"key":"2023011120084436700_B150","doi-asserted-by":"crossref","unstructured":"Yao L, Pike SE, Setsuda J, et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood\u20082000; 96: 1900\u20135.","DOI":"10.1182\/blood.V96.5.1900.h8001900_1900_1905"},{"key":"2023011120084436700_B151","doi-asserted-by":"crossref","unstructured":"Johansson M, Henriksson R, Bergenheim AT, Koskinen LO. Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br J Cancer\u20082000; 83: 826\u201332.","DOI":"10.1054\/bjoc.2000.1354"},{"key":"2023011120084436700_B152","doi-asserted-by":"crossref","unstructured":"Morini M, Albini A, Lorusso G, et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Ther\u20082004; 11: 284\u201391.","DOI":"10.1038\/sj.gt.3302175"},{"key":"2023011120084436700_B153","doi-asserted-by":"crossref","unstructured":"Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J\u20081999; 13: 2195\u2013202.","DOI":"10.1096\/fasebj.13.15.2195"},{"key":"2023011120084436700_B154","doi-asserted-by":"crossref","unstructured":"D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A\u20081994; 91: 3964\u20138.","DOI":"10.1073\/pnas.91.9.3964"},{"key":"2023011120084436700_B155","doi-asserted-by":"crossref","unstructured":"Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol\u20081997; 51: 951\u201362.","DOI":"10.1124\/mol.51.6.951"},{"key":"2023011120084436700_B156","doi-asserted-by":"crossref","unstructured":"Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett\u20082002; 531: 141\u201351.","DOI":"10.1016\/S0014-5793(02)03478-6"},{"key":"2023011120084436700_B157","unstructured":"Li L, Bu S, Backstrom T, Landstrom M, Ulmsten U, Fu X. Induction of apoptosis and G2-M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res\u20082004; 24: 873\u201380."},{"key":"2023011120084436700_B158","unstructured":"Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev\u20082000; 19: 173\u20139."},{"key":"2023011120084436700_B159","doi-asserted-by":"crossref","unstructured":"Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol\u20082004; 53: 209\u201319.","DOI":"10.1007\/s00280-003-0726-5"},{"key":"2023011120084436700_B160","doi-asserted-by":"crossref","unstructured":"Huang CY, Fujimura M, Noshita N, Chang YY, Chan PH. SOD1 down-regulates NF-\u03baB and c-Myc expression in mice after transient focal cerebral ischemia. J Cereb Blood Flow Metab\u20082001; 21: 163\u201373.","DOI":"10.1097\/00004647-200102000-00008"},{"key":"2023011120084436700_B161","doi-asserted-by":"crossref","unstructured":"Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem\u20081995; 38: 2041\u20139.","DOI":"10.1021\/jm00012a003"},{"key":"2023011120084436700_B162","doi-asserted-by":"crossref","unstructured":"Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell\u20082003; 3: 363\u201375.","DOI":"10.1016\/S1535-6108(03)00077-1"},{"key":"2023011120084436700_B163","doi-asserted-by":"crossref","unstructured":"Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol\u20082004; 137: 668\u201374.","DOI":"10.1016\/j.ajo.2003.11.015"},{"key":"2023011120084436700_B164","doi-asserted-by":"crossref","unstructured":"Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun\u20082002; 296: 877\u201382.","DOI":"10.1016\/S0006-291X(02)00940-3"},{"key":"2023011120084436700_B165","doi-asserted-by":"crossref","unstructured":"Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol\u20082001; 132: 378\u201382.","DOI":"10.1016\/S0002-9394(01)01008-X"},{"key":"2023011120084436700_B166","doi-asserted-by":"crossref","unstructured":"Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol\u20082002; 134: 348\u201353.","DOI":"10.1016\/S0002-9394(02)01568-4"},{"key":"2023011120084436700_B167","doi-asserted-by":"crossref","unstructured":"Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med\u20082002; 8: 330\u20134.","DOI":"10.1016\/S1471-4914(02)02362-6"},{"key":"2023011120084436700_B168","doi-asserted-by":"crossref","unstructured":"Gettins PG, Simonovic M, Volz K. Pigment epithelium-derived factor (PEDF), a serpin with potent anti-angiogenic and neurite outgrowth-promoting properties. Biol Chem\u20082002; 383: 1677\u201382.","DOI":"10.1515\/BC.2002.188"},{"key":"2023011120084436700_B169","doi-asserted-by":"crossref","unstructured":"Coljee VW, Rotenberg MO, Tresini M, Francis MK, Cristofalo VJ, Sell C. Regulation of EPC-1\/PEDF in normal human fibroblasts is posttranscriptional. J Cell Biochem\u20082000; 79: 442\u201352.","DOI":"10.1002\/1097-4644(20001201)79:3<442::AID-JCB90>3.0.CO;2-Z"},{"key":"2023011120084436700_B170","doi-asserted-by":"crossref","unstructured":"Abe R, Shimizu T, Yamagishi S, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol\u20082004; 164: 1225\u201332.","DOI":"10.1016\/S0002-9440(10)63210-5"},{"key":"2023011120084436700_B171","doi-asserted-by":"crossref","unstructured":"Abramson LP, Stellmach V, Doll JA, Cornwell M, Arensman RM, Crawford SE. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatr Surg\u20082003; 38: 336\u201342; discussion 336\u201342.","DOI":"10.1053\/jpsu.2003.50104"},{"key":"2023011120084436700_B172","doi-asserted-by":"crossref","unstructured":"Crawford SE, Stellmach V, Ranalli M, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci\u20082001; 114: 4421\u20138.","DOI":"10.1242\/jcs.114.24.4421"},{"key":"2023011120084436700_B173","doi-asserted-by":"crossref","unstructured":"Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004.","DOI":"10.1038\/sj.cgt.7700675"},{"key":"2023011120084436700_B174","doi-asserted-by":"crossref","unstructured":"Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med\u20082003; 9: 774\u201380.","DOI":"10.1038\/nm870"},{"key":"2023011120084436700_B175","doi-asserted-by":"crossref","unstructured":"Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther\u20082003; 8: 72\u20139.","DOI":"10.1016\/S1525-0016(03)00128-X"},{"key":"2023011120084436700_B176","doi-asserted-by":"crossref","unstructured":"Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg\u20082003; 126: 28\u201338.","DOI":"10.1016\/S0022-5223(02)73616-7"},{"key":"2023011120084436700_B177","doi-asserted-by":"crossref","unstructured":"Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther\u20082002; 6: 490\u20134.","DOI":"10.1006\/mthe.2002.0702"},{"key":"2023011120084436700_B178","doi-asserted-by":"crossref","unstructured":"Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol\u20082001; 189: 323\u201333.","DOI":"10.1002\/jcp.10026"},{"key":"2023011120084436700_B179","doi-asserted-by":"crossref","unstructured":"Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun\u20082003; 303: 962\u20137.","DOI":"10.1016\/S0006-291X(03)00446-7"},{"key":"2023011120084436700_B180","doi-asserted-by":"crossref","unstructured":"Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun\u20082004; 316: 573\u20139.","DOI":"10.1016\/j.bbrc.2004.02.076"},{"key":"2023011120084436700_B181","doi-asserted-by":"crossref","unstructured":"Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell\u20081998; 92: 391\u2013400.","DOI":"10.1016\/S0092-8674(00)80931-9"},{"key":"2023011120084436700_B182","doi-asserted-by":"crossref","unstructured":"Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A\u20082000; 97: 12227\u201332.","DOI":"10.1073\/pnas.220399597"},{"key":"2023011120084436700_B183","doi-asserted-by":"crossref","unstructured":"Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science\u20081990; 247: 77\u20139.","DOI":"10.1126\/science.1688470"},{"key":"2023011120084436700_B184","unstructured":"Hagedorn M, Zilberberg L, Wilting J, et al. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res\u20082002; 62: 6884\u201390."},{"key":"2023011120084436700_B185","doi-asserted-by":"crossref","unstructured":"Chadderton NS, Stringer SE. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol\u20082003; 35: 1052\u20135.","DOI":"10.1016\/S1357-2725(02)00299-6"},{"key":"2023011120084436700_B186","doi-asserted-by":"crossref","unstructured":"Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology\u20081991; 129: 896\u2013900.","DOI":"10.1210\/endo-129-2-896"},{"key":"2023011120084436700_B187","doi-asserted-by":"crossref","unstructured":"Pan H, Nguyen NQ, Yoshida H, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci\u20082004; 45: 2413\u20139.","DOI":"10.1167\/iovs.03-1001"},{"key":"2023011120084436700_B188","doi-asserted-by":"crossref","unstructured":"Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin\/growth hormone\/placental lactogen family in angiogenesis. J Endocrinol\u20082002; 173: 219\u201338.","DOI":"10.1677\/joe.0.1730219"},{"key":"2023011120084436700_B189","doi-asserted-by":"crossref","unstructured":"Struman I, Bentzien F, Lee H, et al. Opposing actions of intact and N-terminal fragments of the human prolactin\/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A\u20081999; 96: 1246\u201351.","DOI":"10.1073\/pnas.96.4.1246"},{"key":"2023011120084436700_B190","doi-asserted-by":"crossref","unstructured":"D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A\u20081995; 92: 6374\u20138.","DOI":"10.1073\/pnas.92.14.6374"},{"key":"2023011120084436700_B191","doi-asserted-by":"crossref","unstructured":"D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol\u20081999; 13: 692\u2013704.","DOI":"10.1210\/mend.13.5.0280"},{"key":"2023011120084436700_B192","doi-asserted-by":"crossref","unstructured":"Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol\u20082002; 55: 300\u20134.","DOI":"10.1136\/mp.55.5.300"},{"key":"2023011120084436700_B193","doi-asserted-by":"crossref","unstructured":"Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta\u20082000; 1477: 267\u201383.","DOI":"10.1016\/S0167-4838(99)00279-4"},{"key":"2023011120084436700_B194","doi-asserted-by":"crossref","unstructured":"Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene\u20082002; 21: 2245\u201352.","DOI":"10.1038\/sj.onc.1205291"},{"key":"2023011120084436700_B195","doi-asserted-by":"crossref","unstructured":"Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell\u20082003; 114: 171\u201380.","DOI":"10.1016\/S0092-8674(03)00551-8"},{"key":"2023011120084436700_B196","doi-asserted-by":"crossref","unstructured":"Moses MA, Wiederschain D, Wu I, et al. Troponin I is present inhuman cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A\u20081999; 96: 2645\u201350.","DOI":"10.1073\/pnas.96.6.2645"},{"key":"2023011120084436700_B197","doi-asserted-by":"crossref","unstructured":"Feldman L, Rouleau C. Troponin I inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptor. Microvasc Res\u20082002; 63: 41\u20139.","DOI":"10.1006\/mvre.2001.2364"},{"key":"2023011120084436700_B198","doi-asserted-by":"crossref","unstructured":"Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood\u20081999; 94: 2461\u20138.","DOI":"10.1182\/blood.V94.7.2461.419a26_2461_2468"},{"key":"2023011120084436700_B199","doi-asserted-by":"crossref","unstructured":"Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med\u20081998; 188: 2349\u201356.","DOI":"10.1084\/jem.188.12.2349"},{"key":"2023011120084436700_B200","doi-asserted-by":"crossref","unstructured":"Yao L, Pike SE, Pittaluga S, et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother\u20082002; 51: 358\u201366.","DOI":"10.1007\/s00262-002-0294-2"},{"key":"2023011120084436700_B201","doi-asserted-by":"crossref","unstructured":"Yao L, Pike SE, Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol\u20082002; 71: 47\u201353.","DOI":"10.1189\/jlb.71.1.47"},{"key":"2023011120084436700_B202","doi-asserted-by":"crossref","unstructured":"Xiao F, Wei Y, Yang L, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther\u20082002; 9: 1207\u201313.","DOI":"10.1038\/sj.gt.3301788"},{"key":"2023011120084436700_B203","doi-asserted-by":"crossref","unstructured":"Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ Jr. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist\u20081999; 4: 501\u20138.","DOI":"10.1634\/theoncologist.4-6-501"},{"key":"2023011120084436700_B204","doi-asserted-by":"crossref","unstructured":"Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol\u20082003; 21: 223\u201331.","DOI":"10.1200\/JCO.2003.12.120"},{"key":"2023011120084436700_B205","doi-asserted-by":"crossref","unstructured":"Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res\u20082004; 10: 33\u201342.","DOI":"10.1158\/1078-0432.CCR-0736-3"},{"key":"2023011120084436700_B206","doi-asserted-by":"crossref","unstructured":"Bukowski RM. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs\u20082003; 12: 1403\u201311.","DOI":"10.1517\/13543784.12.8.1403"},{"key":"2023011120084436700_B207","doi-asserted-by":"crossref","unstructured":"Chamberlain J. Transforming growth factor-\u03b2: a promising target for anti-stenosis therapy. Cardiovasc Drug Rev\u20082001; 19: 329\u201344.","DOI":"10.1111\/j.1527-3466.2001.tb00074.x"},{"key":"2023011120084436700_B208","unstructured":"Westphal JR. Technology evaluation: ABT-510, Abbott. Curr Opin Mol Ther\u20082004; 6: 451\u20137."},{"key":"2023011120084436700_B209","doi-asserted-by":"crossref","unstructured":"Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy\u20082003; 23: 165\u201372.","DOI":"10.1592\/phco.23.2.165.32088"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/10\/3967\/2530785\/3967-3979.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/10\/3967\/2530785\/3967-3979.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T21:08:32Z","timestamp":1673471312000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/10\/3967\/517946\/Endogenous-Inhibitors-of-Angiogenesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,15]]},"references-count":209,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,5,16]]},"published-print":{"date-parts":[[2005,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-04-2427","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,15]]}}}